Moderna Inc. surged 14.36% on Tuesday to close at $158.83 after Wolfe Research raised its rating on the stock to Peer Perform from Underperform. The $19.94 increase boosted Moderna's quoted equity value by approximately $8.0 billion.
Stock move, valuation, trial evidence and cash runway
Financial figures reported July 31, 2026. A $950M settlement payment followed in July.
S&P Global consensus: Hold, 23 analysts; average target implies 37.2% downside from Tuesday's close.
| Measure | Reading | Investor meaning |
|---|---|---|
| INTerpath-001 enrollment | 1,137 patients | First positive Phase 3 individualized mRNA cancer-therapy readout |
| Treatment design | Up to 34 neoantigens; nine intismeran doses | Patient-specific manufacturing adds cost and turnaround risk |
| Phase 2b five-year result | 49% lower recurrence/death risk; 59% lower distant-metastasis/death risk | Supports mechanism, but Phase 3 effect size remains undisclosed |
| Moderna reaction | +176.97% on Aug. 19 | Largest direct platform repricing |
| Merck reaction | +12.6% on Aug. 19 | Extends the Keytruda franchise opportunity |
| BioNTech reaction | about +22% on Aug. 19 | Read-through for personalized mRNA oncology |
The August 25 rally added about $8.0 billion in value. Since the pre-readout close, the gain is about $38.3 billion. That premium now depends on regulatory timing, manufacturing economics and success beyond melanoma.
Hazard ratios, absolute event rates and overall-survival data are pending. Personalized production may constrain margins. Other tumors may not reproduce the melanoma result. Cash burn remains material.
Market data: August 25, 2026, 4:00 p.m. EDT
After-hours: 7:59 p.m. EDT • Dashboard: August 26, 2026, 01:10 EDT
+21.81% • +$0.53
−1.68% from close
7.7× 12.9M 3-month average
≈$211M added Tuesday
The close remains 65.0% below the 52-week high despite Tuesday’s surge.
Rezolve says its database provides indexing and pipelines behind Google Cloud Web3 datasets.
Preliminary H1 covers 35.3% of guidance. H2 must run about 83% above H1.
| Measure | Numerator | Denominator | Multiple |
|---|---|---|---|
| Market cap / FY 2025 revenue | $1.18B | $46.8M | 25.2× |
| Market cap / FY 2026 guidance | $1.18B | $360M | 3.3× |
| Tuesday value gain / FY26 guide | ≈$211M | $360M | 0.59× |
| Analyst target / close | $10.50 avg. | $2.96 | 3.55× |
Five-analyst consensus: Strong Buy; target range $7–$15. Targets predate this catalyst.
Investor read: Google validates the technology, but September must validate economics. Watch recognized revenue, gross margin, cash conversion, outstanding shares and continued support for the $360 million outlook.
Sources: Rezolve AI investor releases dated July 27, August 6 and August 25, 2026; Rezolve AI 2025 Form 20-F; S&P Global Market Intelligence and Nasdaq UTP data displayed by StockAnalysis. Derived figures may differ due to rounding.
NYSE:BABA · Market data through August 25, 2026, 20:00 EDT
The issue raises about $10.21 billion for chips, infrastructure and models. That equals 6.6% of trailing revenue and 18.1% of Alibaba's three-year AI plan.
Placement as a share of the $56.54B three-year AI commitment
| Measure | Value |
|---|---|
| New shares | 710M |
| Offer price | HK$112.70 |
| Discount | 8.4% |
| Net cash | HK$79.7B |
| Expected close | Aug. 26 |
| June quarter | Value |
|---|---|
| Group revenue | $39.6B |
| Revenue growth | +9% |
| AI cloud revenue | $7.1B |
| Cloud growth | +45% |
| Cloud adj. EBITA | $830M |
| EBITA growth | +133% |
| Analysts | Value |
|---|---|
| Consensus | Strong Buy |
| Coverage | 40 |
| Average target | $186.68 |
| Implied upside | +56.3% |
| Low / high | $92.74 / $237.81 |
| Date | Close | Move | Volume |
|---|---|---|---|
| Aug. 20 | $130.53 | +1.26% | 28.1M |
| Aug. 21 | $119.34 | −8.57% | 32.4M |
| Aug. 24 | $118.47 | −0.73% | 23.9M |
| Aug. 25 | $119.44 | +0.82% | 15.8M |
The ADR remains 8.5% below its Aug. 20 close.
The planned commitment equals 5.3% of market value, 4.3 times trailing revenue and 5.4 quarters of the latest capital-spending pace.
| Site | 125,000 acres |
| Launch complexes | 5 |
| Launch pads | 10 |
| Direct jobs | 3,000 |
| Average salary | $92,600 |
| Indirect jobs | 8,100 |
| Direct local payments | >$820M |
More Starship slots can expand satellite deployment and payload revenue. Cash flow depends on launch reliability, customer demand and the final spending schedule.
| Q2 revenue | $7.81B |
| Revenue growth | 92% |
| Adjusted EBITDA | $3.54B |
| Net loss | $541M |
| Q2 capex | $18.37B |
| Backlog | $47.5B |
| Average target | $213.50 |
| Low target | $75 |
| High target | $450 |
| Forward P/E | 106.3× |
Sources: Louisiana Economic Development, Reuters, SpaceX's August 4 SEC filing, StockAnalysis and S&P Global analyst data. Calculations use the August 25 close and approximately 13.57 billion shares. Figures may not sum because of rounding.
The 5.4% move equals about $11.50 per share. It is an options estimate, not a forecast or a guaranteed trading range.
Fiscal Q2 FY27 results
17:00 EDT · 14:00 PDT
Conference call and webcast
At Tuesday's close, the 7.4% historical response equals about ±$15.77 and roughly $382 billion of equity value.
The $280 billion implied equity swing is roughly 3.1 times Nvidia's $91 billion quarterly revenue guide.
A modest change in revenue growth or margin expectations can therefore move more value than several quarters of sales.
| Metric | Reference |
|---|---|
| Q1 revenue | $81.6B |
| Year-over-year growth | 85% |
| Data Center revenue | $75.2B |
| Data Center growth | 92% |
| Q2 revenue guide | $91.0B ±2% |
| Q2 non-GAAP margin | 75.0% ±0.5 pt |
| Average target | $304.73 |
| Target range | $180–$500 |
| Forward P/E | 20.77 |
Sources: Nvidia investor relations, Reuters options-market reporting, StockAnalysis and S&P Global analyst data. Calculations use the August 25 close of $213.05 and approximately 24.22 billion shares. Figures may not sum because of rounding.
| Metric | Reading | Period |
|---|---|---|
| Total revenue | $1.22B | Q2 2026 |
| Subscription & services | $555M | Q2 2026 |
| Share of net revenue | 48% | Q2 2026 |
| Adjusted EBITDA | $207.8M | Q2 2026 |
| Net loss | −$359.5M | Q2 2026 |
| Trading-volume share | 10.3% | Q2 2026 |
Interpretation: Base can distribute the assets across wallets and DeFi protocols. The investor case still needs disclosed volume, take rate and contribution margin.
| Company | August 25 close | Day move | Market cap | Forward P/E | Analyst target upside |
|---|---|---|---|---|---|
| Coinbase | $187.16 | +4.28% | $49.38B | 162.8× | +5.0% |
| Cboe Global Markets | $308.82 | +0.24% | $32.25B | 21.3× | +2.1% |
| Intercontinental Exchange | $161.78 | −0.74% | $90.82B | 19.7× | +14.6% |
| Nasdaq | $98.73 | −0.06% | $55.19B | 22.6× | +11.2% |
| CME Group | $277.32 | −0.66% | $99.72B | 22.5× | +2.1% |
Peer data are as of the August 25 U.S. close. The comparison shows Coinbase's greater earnings sensitivity to digital-asset activity and product adoption.
Consensus across 34 analysts, with an average target of $196.55.
The target implied 5.0% upside from the August 25 close. That is smaller than the stock's single-day 4.28% move.
Tuesday's price action treated tokenized equities as a credible extension of Coinbase's platform. The measurable evidence is the stock move, not product revenue. With only four securities and no disclosed fee schedule, adoption data now matter more than launch-day attention.
| Q2 2026 | Reading |
|---|---|
| Net sales | $26.54B · +5.3% |
| Comparable sales | +3.8% |
| Comparable traffic | +3.6% |
| Store comparable sales | +2.7% |
| Digital comparable sales | +8.7% |
| Operating margin | 9.6%* |
| Consensus | Hold |
| Average target | $161.62 |
| Range | $121–$200 |
| Analysts | 38 |
| Average target vs. close | −1.1% |
| Product review | Specific control changes |
| Halloween quarter | Traffic and markdowns |
| Digital channel | Whether 8.7% growth holds |
| Guidance | ~5% sales growth |
| Next earnings | Expected Nov. 18 |
The reverse split changed the share count, not the economics. The first adjusted close remained deeply below the exchange's $1 reference level.
Class B changed from roughly 23.88 million to 4.78 million shares. Options and warrants were adjusted proportionally; par value was unchanged.
Volume reached 24.31 million shares by 15:23 EDT on Aug. 25. The reference close was $0.468 on a split-adjusted basis.
Estimated Class A values use approximately 135.98 million post-split shares. The Aug. 25 decline erased about $11.0 million. The treasury held 278.0314 bitcoin worth about $21.6 million on Aug. 23.
| Metric | Latest period | Reading | Investor signal |
|---|---|---|---|
| Revenue | Q2 2026 | $34.841M | +34.8% YoY |
| Gross profit | Q2 2026 | about $8.8M | roughly 25% margin |
| Net loss attributable to common | Q2 2026 | −$21.654M | 62.2% of revenue |
| Operating cash flow | H1 2026 | −$9.885M | cash-consuming |
| Cash and equivalents | June 30, 2026 | about $36.8M | below planned campus funding need |
No reliable current sell-side consensus price target was available at publication.
| Metric | Actual | Street | Beat |
|---|---|---|---|
| Revenue | $4.354B | $4.27B | +2.0% |
| Adjusted EPS | $4.03 | $3.58 | +12.6% |
| Online Ecosystem | $2.6B | — | +17% YoY |
| Credit Karma | $743M | — | +16% YoY |
The definition change narrows the apparent EPS miss. The revenue midpoint of $4.304B still trails the $4.35B consensus by about 1.1%.
| Firm / group | Rating | Target | Upside vs close |
|---|---|---|---|
| Jefferies | Buy | $500 | 39.3% |
| Citi | Buy | $457 | 27.3% |
| 35-analyst avg. | Buy | $446.02 | 24.3% |
| TD Cowen | Hold | $328 | −8.6% |
Market close · August 25, 2026 · 16:00 EDT
Ontario named uranium as possible trade leverage. Oklo rallied, though no cutoff or new Oklo contract was announced.
The session's added value equaled 6.7× Oklo's $126.9M first-half capital spending. That is a sentiment move, not realized cash flow.
| Metric | Amount |
|---|---|
| Cash + marketable securities | $3.01B |
| H1 ATM equity proceeds | $1.85B |
| H1 operating cash use | $65.5M |
| H1 capital spending | $126.9M |
| 2026 operating cash-use guide | $120–150M |
| 2026 PP&E guide | $400–500M |
Balance-sheet figures through June 30, 2026. Source: Oklo Form 10-Q and Q2 call.
| Measure | Target / view |
|---|---|
| Consensus | Buy · 15/9/1 |
| Average target | $79.88 · +80% |
| Median target | $81.50 · +84% |
| Truist | Hold · $51 |
| H.C. Wainwright | Buy · $90 |
| Canaccord | Buy · $100 |
Latest compiled targets available August 25; recent firm calls dated August 10.
Policy riskHALEU accessGroves executionAurora scheduleEquity dilution
Oklo has enough liquidity to fund near-term work, but its $8.23B value still depends on regulatory progress and future commercial deployment. The uranium threat supports the strategic case for domestic fuel. It does not itself create revenue. A reversal in trade rhetoric could therefore unwind part of Tuesday's gain.
Sources: Yahoo Finance close and volume; Oklo Q2 2026 Form 10-Q; Oklo Groves first-criticality release; Reuters and AP trade reporting; S&P Global analyst compilation. All market figures as of August 25, 2026, 16:00 EDT.
Tuesday's market-value gain alone equals 4.35× funded backlog and 476× first-quarter revenue. Wednesday's report must show how signed work reaches the income statement.
| Metric | Q1 2026 / Mar. 31 | Read-through |
|---|---|---|
| Revenue | $0.594M | +57% year on year |
| Cost of revenue | $5.01M | Scale not yet economic |
| Net loss | -$7.71M | Early-stage spending |
| Cash | $124.9M | Before $150M IPO |
| Funded backlog | $65M | Binding work |
| Firm | Rating | Target |
|---|---|---|
| RBC Capital | Outperform | $11 |
| BofA Securities | Buy | $15 |
| Stifel | Buy | $16 |
| Barclays | Overweight | $17 |
| Evercore ISI | Outperform | $17 |
| Goldman Sachs | Buy | $18 |
Binding supply of multiple metric tons of TRISO fuel through 2031 for Radiant's one-megawatt Kaleidos microreactors.
NYSE: RBRK · Fiscal Q2 2027 setup · Market snapshot: August 25, 2026, 14:33 EDT
The chart uses verified closes through Aug. 21 and the Aug. 25 intraday snapshot. The stock remains about 26% above its July 31 close despite Tuesday's drop.
| Metric | Latest / guide | Signal |
|---|---|---|
| Q1 revenue | $387.1M; +39% YoY | Growth |
| Q1 subscription ARR | $1.57B; +32% YoY | Core demand |
| Q1 free cash flow | $73.6M; 19% margin | Leverage |
| Q2 revenue guide | $395M–$397M | +27.7% YoY at midpoint |
| Q2 adjusted EPS guide | $0.03–$0.05 | Profitable |
| FY27 revenue guide | $1.638B–$1.648B | Valuation base |
| FY27 free-cash-flow guide | $293M–$303M | ≈18.1% midpoint margin |
| Firm / sample | Rating | Target | Implied move |
|---|---|---|---|
| Wells Fargo | Overweight | $120 | +31.9% |
| Oppenheimer | Outperform | $120 | +31.9% |
| Cantor Fitzgerald | Overweight | $120 | +31.9% |
| KeyBanc | Overweight | $112 | +23.1% |
| 27-analyst consensus | Strong Buy | $103.07 | +13.3% |
ARR growth below expectations, cautious forward guidance, or heavier investment could compress the revenue multiple. The stock's August rally also raises the threshold for a favorable post-earnings reaction.
Sources: Rubrik investor relations, Yahoo Finance, Wells Fargo research summary, S&P Global analyst compilation and company guidance. Time-sensitive market figures are stamped August 25, 2026, 14:33 EDT.
| Cash + marketable securities | $2.364B |
| Cash as share of market cap | 40.5% |
| Q2 revenue | $10.2M |
| Q2 R&D expense | $67.2M |
| Q2 net loss | $91.2M |
| CASGEVY Q2 global revenue | $76M |
| Firm | Latest action | Rating | Target | Implied return |
|---|---|---|---|---|
| Citizens | Aug. 25 | Market Outperform | $80 | +32.5% |
| Goldman Sachs | Aug. 10 | Hold | $55 | −8.9% |
| Bank of America | Aug. 5 | Buy | $82 | +35.8% |
| Morgan Stanley | Aug. 4 | Hold | $60 | −0.6% |
| Piper Sandler | Aug. 4 | Buy | $110 | +82.2% |
A durable ANGPTL3 response could add an in-vivo cardiovascular franchise beside CASGEVY. Tuesday's move capitalized that possibility before the data.
CTX310 is early-stage. Small cohorts, safety findings or weaker durability could erase the move. Clinical value remains distinct from commercial value.
$319 million gained versus $2.364 billion of liquidity. The stock's one-day market-value increase equals roughly 13.5% of reported cash and securities. Citizens' $80 target adds another $1.90 billion of implied equity value from the midday base. The August 28 data therefore tests whether investors will assign meaningful value to CTX310 before later-stage evidence.
Sources: CRISPR Therapeutics Q2 2026 business update; Google Finance; Citizens research note reported by Investing.com. Calculations may differ slightly because market capitalization and shares outstanding are rounded.
The board authorized purchases of Class B stock through Aug. 21, 2027. No minimum purchase is required. The board may modify, pause or end the program without notice.
| Firm | Action | Rating | Target | Date | Vs. $1.89 |
|---|---|---|---|---|---|
| Freedom Broker | Upgrade | Hold | $2 | Aug. 16, 2026 | +5.8% |
| H.C. Wainwright | Reiterate | Buy | $6 | Feb. 2, 2026 | +217.5% |
Coverage is sparse. The target spread highlights unusually wide uncertainty around commercialization and valuation.
Market snapshot: August 25, 2026, 11:31 EDT · U.S. regular session
Up 8.63% from a $35.17 prior close.
About $1.96B added during the move.
Shares traded by 11:31 EDT on August 25.
Versus 22.68× for Dell and 21.50× for Cisco.
The $68.5 billion midpoint implies 75.4% growth. Cisco’s October availability is a channel catalyst; no order value has been disclosed.
Consensus: Hold · Average target $42.38 · Implied upside 10.9% from $38.21.
| Company | Price | Daily move | Market value | Forward P/E |
|---|---|---|---|---|
| Super Micro Computer (NASDAQ: SMCI) | $38.21 | +8.63% | $24.71B | 8.81× |
| Dell Technologies (NYSE: DELL) | $453.27 | +4.64% | $292.88B | 22.68× |
| Cisco Systems (NASDAQ: CSCO) | $110.97 | +0.67% | $437.38B | 21.50× |
Prices and valuation metrics: StockAnalysis snapshots at 11:30–11:31 EDT, August 25, 2026. SMCI outperformed the equal-weight daily move of Dell and Cisco by about 6.0 percentage points.
Cisco supplies distribution and enterprise validation. Supermicro supplies dense rack-scale compute and liquid cooling. The commercial link is direct, but not yet quantified: an October product path can widen customer access, while revenue depends on orders, pricing, delivery and margin.
| Q4 FY2026 sales | $11.1B | +93.2% YoY |
| Q4 FY2026 gross margin | 17.5% | +8.0 points YoY |
| Q1 FY2027 sales guide | $14.5–$15.5B | Midpoint +34.9% vs. Q4 |
| FY2027 sales guide | $65–$72B | +66.4% to +84.3% |
Cisco disclosed no committed orders, pricing or margin. Taiwan’s August 24 server-export case adds compliance scrutiny: prosecutors allege 74 of 130 B300 systems reached China through indirect routes, while customs stopped 56. Supermicro says it is not an investigation target and is not accused of wrongdoing.
Sources: Cisco, Supermicro results, Reuters, StockAnalysis market data and analyst consensus. Time-sensitive market figures are stamped August 25, 2026, 11:30–11:31 EDT.
| Tier | From | Battery* | Investor read |
|---|---|---|---|
| fēnix 9 | $999.99 | 29 days | Premium base intact |
| Pro AMOLED | $1,099.99 | 31 days | Optional inReach |
| Pro Solar | $1,099.99+ | 57 days | Highest endurance |
| Signal | Current evidence | Bull case | Risk |
|---|---|---|---|
| Demand | Launch from $999.99 | Premium upgrades restart Outdoor growth | Longer replacement cycles |
| Mix | Pro, solar and inReach options | Higher attach and average selling price | Promotions dilute margin |
| Valuation | 30.04× trailing earnings | Guidance beat supports multiple | Hold-heavy consensus caps rerating |
| Balance sheet | $4.4B cash and securities at June 27 | Funds product cadence and buybacks | Inventory absorbs cash |
| Edition | Price |
|---|---|
| Standard | $79.99 |
| Ultimate | $99.99 |
| Upgrade | +$20 / +25% |
| Metric | Reading |
|---|---|
| Q1 FY27 net bookings | $1.39bn · −3% YoY |
| Q1 GAAP revenue | $1.53bn |
| Q1 GAAP net result | −$34.1m |
| Recurrent share of bookings | 84% |
| FY27 GAAP revenue outlook | $7.9–8.1bn |
| FY27 operating cash flow | >$1.0bn |
| Firm · date | View | Target |
|---|---|---|
| JPMorgan · Aug 11 | Overweight | $310 |
| Roth · Aug 10 | Buy | $300 |
| Wells Fargo · Aug 10 | Overweight | $300 |
| Oppenheimer · Aug 10 | Outperform | $280 |
| BTIG · Aug 10 | Buy | $313 |
High preview engagement converts into stronger pre-orders and an above-plan Ultimate mix. A 10m-edition upgrade scenario adds $200m of gross consumer spending.
The preview stabilizes marketing control. Fiscal 2027 bookings remain near the $8.1bn midpoint and the November 19 launch holds.
Technical criticism, weak premium mix or another delay narrows the valuation gap. Muted engagement after Aug. 27 is the first observable warning.
The administration is larger than one listed lender’s balance-sheet exposure. The key variables are fund-level loan concentration, project completion and the time required to turn first-mortgage security into cash.
Bars use separate scales: the first two compare borrower liabilities and CNI’s direct loan; the ASIC bar is a market snapshot, not Bathla exposure.
| Item | Current reading | Investor implication |
|---|---|---|
| Administrator | Teneo; Universal Property Group and Raj & Jai Construction | Control shifts to project stabilisation and creditor recovery |
| Bathla pipeline | 5,000+ homes on company website | Completion delays can tighten western Sydney supply |
| Centuria security | First mortgages; partial cross-collateralisation | Recovery depends on asset values and timing |
| ASIC private-credit survey | 22 managers, 52 funds, ~A$76bn AUM | Valuation and concentration are active enforcement themes |
| RBA system view | Private credit below 2% of financial-system assets | Systemic risk appears contained; fund-level risk can still be material |
| Next catalyst | First creditors’ meeting reported for 4 Sep 2026 | Watch secured debt, cash needs and project-by-project recovery |
The One Piece drop matters most as a SNKRS traffic and full-price sell-through test.
Watch inventory duration, app ranking, resale premium and markdowns—not search volume alone.
| Marker | Target | vs. close |
|---|---|---|
| JPM / Wells | $40 | -1.8% |
| Median | $47 | +15.3% |
| Average | $50.66 | +24.3% |
| Bernstein | $68 | +66.9% |
Bull case: quick full-price sell-through would support Nike's effort to rebuild scarcity and digital engagement. Bear case: a tiny allocation can sell out without improving broad demand. JD Sports' 6.8% North American comparable-sales fall keeps the recovery bar high.
| Firm | Rating | Target |
|---|---|---|
| Jefferies | Buy | $120 |
| Raymond James | Buy | $130 |
| Deutsche Bank | Hold | $113 |
| Signal | What it means | Next check |
|---|---|---|
| CPI-W | The statutory COLA input; July is only one of three deciding months. | August CPI — Sept. 11 |
| Gross benefit | A 3.5% midpoint implies about $73 more monthly for an average retired worker. | Official COLA — Oct. 14 |
| Net benefit | Medicare Part B premiums can absorb part of the headline increase. | Premium notice — autumn |
| Retail read-through | Helpful for nominal budgets, but food, fuel and rent can take the cash first. | WMT Q3 — next earnings |
![UK Stock Market Today 26/08/2026 [UPDATE: 09:01 BST] [Miners Offset Oil Majors as Brent Slides Below $86]](https://ts2.tech/wp-content/uploads/2026/08/UK-market-dashboard-2026-08-26-0901-480x384.jpg "UK Stock Market Today 26/08/2026 [UPDATE: 09:01 BST] [Miners Offset Oil Majors as Brent Slides Below $86]")
![US Stock Market Today 08/26/2026 [UPDATE: 03:08 EDT] [QQQ Halves Loss as Semtech Reclaims 4.5% Overnight Gain]](https://ts2.tech/wp-content/uploads/2026/08/US-market-dashboard-2026-08-26-0307-480x384.jpg "US Stock Market Today 08/26/2026 [UPDATE: 03:08 EDT] [QQQ Halves Loss as Semtech Reclaims 4.5% Overnight Gain]")
